Acute Nonarteritic Anterior Ischemic Optic Neuropathy and Exposure to Phosphodiesterase Type 5 Inhibitors

Journal of Sexual Medicine

Volumn 12, Issue 1, 2015, Pages 139-151

  Campbell, Ulka B ^a   Walker, Alexander M ^b   Gaffney, Michael ^a   Petronis, Kenneth R ^a   Creanga, Dana ^c   Quinn, Sheila ^a   Klein, Barbara E K ^d   Laties, Alan M ^e   Lewis, Michael ^f   Sharlip, Ira D ^g   Kolitsopoulos, Francesca ^a   Klee, Brian J ^a   Mo, Jingping ^a   Reynolds, Robert F ^a  

^a PFIZER INC   (United States)

^b World Health Information Science Consultants   (United States)

^c SYNEOS HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f EPES Epidemiology GmbH   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Case Crossover Study; Erectile Dysfunction (ED); Nonarteritic Anterior Ischemic Optic Neuropathy (NAION); Phosphodiesterase Type 5 Inhibitors (PDE5i); Sildenafil

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; AGED; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ARTICLE; CASE CROSSOVER STUDY; CLINICAL STUDY; COMORBIDITY; DRUG EXPOSURE; DRUG HALF LIFE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SMOKING; TOPICAL TREATMENT; CASE CONTROL STUDY; CHEMICALLY INDUCED; ERECTILE DYSFUNCTION; OPTIC NEUROPATHY, ISCHEMIC; PATHOLOGY; STATISTICAL MODEL; UNITED STATES;

AGED; CASE-CONTROL STUDIES; ERECTILE DYSFUNCTION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OPTIC NEUROPATHY, ISCHEMIC; PHOSPHODIESTERASE 5 INHIBITORS; RISK FACTORS; UNITED STATES;

EID: 84923191251     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12726     Document Type: Article

References (19)

1. Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, Sharlip I, Althof SE, Andersson KE, Brock G, Broderick G, Burnett A, Buvat J, Dean J, Donatucci C, Eardley I, Fugl-Meyer KS, Goldstein I, Hackett G, Hatzichristou D, Hellstrom W, Incrocci L, Jackson G, Kadioglu A, Levine L, Lewis RW, Maggi M, McCabe M, McMahon CG, Montague D, Montorsi P, Mulhall J, Pfaus J, Porst H, Ralph D, Rosen R, Rowland D, Sadeghi-Nejad H, Shabsigh R, Stief C, Vardi Y, Wallen K, Wasserman M. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010;7:3572-3588.
2. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004;110:3149-3155.
3. Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006;3:12-27.
4. Moschos MM, Margetis I. Bilateral simultaneous anterior ischemic optic neuropathy associated with sildenafil. Case Rep Ophthalmol 2011;2:262-265.
5. Felekis T, Asproudis I, Katsanos K, Tsianos EV. A case of nonarteritic anterior ischemic optic neuropathy of a male with family history of the disease after receiving sildenafil. Clin Ophthalmol 2011;5:1443-1445.
6. Taratini A, Faraoni A, Menchini F, Lanzetta P. Bilateral simultaneous nonarteritic anterior ischemic optic neuropathy after ingestion of sildenafil for erectile dysfunction. Case Rep Med 2012;2012:747658.
7. Gani J, Perlis N, Radomski SB. Urologic medications and ophthalmologic side effects: A review. Can Urol Assoc J 2012;6:53-58.
8. Miller NR, Arnold AC. Current concepts in the diagnosis, pathogenesis, and management of nonartertic anterior ischaemic optic neuropathy. Eye 2014; doi: 10.1038/eye.2014.144.
9. Gorkin L, Hvidsten K, Sobel RE, Siegel R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 2006;60:500-503.
10. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: Review of 67 placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010;64:240-255.
11. Mittleman MA, Maclure M, Lewis MA, Hall GC, Moore N, Giuliano F, Porst H, Hedelin H, Martin-Morales A, Sobel RE, Reynolds R, Glasser DB. Cardiovascular outcomes among sildenafil users: Results of the International Men's Health Study. Int J Clin Pract 2008;62:367-373.
12. Hazell L, Cornelius V, Wilton LV, Shakir SAW. The general safety of tadalafil as prescribed in general practice in England: Results from a prescription-event monitoring study involving 16 129 patients. BJU Int 2009;103:506-514.
13. Boshier A, Wilton LV, Shakir SAW. Evaluation of the safety of sildenafil for male erectile dysfunction: Experience gained in general practice use in England in 1999. BJU Int 2004;93:796-801.
14. Maclure M. The case-crossover design: A method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-153.
15. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000;21:193-221.
16. Consiglio GP, Burden AM, Maclure M, McCarthy L, Cadarette SM. Case-crossover study design in pharmacoepidemiology: Systematic review and recommendations. Pharmacoepidemiol Drug Saf 2013;22:1146-1153.
17. Willis GB. Cognitive interviewing: A tool for improving questionnaire design. Thousand Oaks, CA: SAGE Publications, Inc; 2004.
18. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 1994;14:38-44.
19. Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Opthalmol 1997;123:103-107.